BackCOSCIENS Biopharma Overview

COSCIENS Biopharma Other Current Liabilities

Track COSCIENS Biopharma's other current liabilities ($1.5M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$1.51M
↓ 58.76% YoYΔ $-2.16M vs prior year quarter

Peer trimmed avg / median

Loading

COSCIENS Biopharma Other Current Liabilities History

Loading

COSCIENS Biopharma vs. peers: Other Current Liabilities Comparison

Loading

COSCIENS Biopharma Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

COSCIENS Biopharma (CSCI) FAQ

As of the most recent data (June 2026), CSCI shows a other current liabilities of $1.5M. That compares with $3.7M in the prior-year period — down 58.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CSCI's other current liabilities is now $1.5M (was $3.7M) — a 58.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether COSCIENS Biopharma is outperforming or lagging.

Tracking CSCI's other current liabilities over time shows whether COSCIENS Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $1.5M That compares with $3.7M in the prior-year period — down 58.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has COSCIENS Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $1.5M) with ownership activity and broader fundamentals.

COSCIENS Biopharma's other current liabilities is $1.5M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.